ARTICLE | Clinical News
MT228: Phase I started
August 30, 2010 7:00 AM UTC
Eisai's Morphotek Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate intralesional MORAb-028 for three 5-day courses over a 30-day cycle in 18 patients. Morphotek li...